Veradermics reports $819.9 million in cash and securities, sees funding into 2030

Veradermics, Incorporated (NYSE: MANE) said on August 11, 2026 that it held $819.9 million in cash, cash equivalents and marketable securities at June 30. The company says that is enough to fund operations into 2030, through several Phase 3 readouts and a possible launch of VDPHL01, its extended-release oral minoxidil for pattern hair loss. The figure splits into $319.3 million of cash and equivalents and $500.6 million of marketable securities, according to the quarterly filing. The release says the total includes net proceeds from a follow-on offering in the quarter, and that the company raised approximately $472.0 million in gross proceeds in May 2026 through that offering and a concurrent private placement. The balance reflects those financings, not product revenue.

The quarter's losses

The results release reports a net loss of $23.5 million for the second quarter of 2026, compared with $15.6 million a year earlier. Research and development expense was $18.6 million, against $14.3 million. General and administrative expense rose to $10.9 million from $1.7 million.

The full year shows the same direction. The annual report gives research and development expense of $62.1 million for 2025, up from $23.3 million in 2024. The 2025 net loss was $70.0 million, against $26.5 million, and cash used in operations was $71.6 million, against $23.7 million.

The trials behind the runway

The company's best recent evidence is Study '207, an open-label Phase 2 in women with mild-to-moderate pattern hair loss, which reported topline results in July 2026. The release calls it the first successful clinical demonstration of an oral treatment for female pattern hair loss in the United States. Women took 4.5 mg of VDPHL01 once or twice daily for six months. At month six, the mean increase in non-vellus target area hair count was 22.7 hairs per square centimeter with the once-daily dose and 23.3 with the twice-daily dose. Between 88.9% and 90.0% of participants rated their hair coverage as improved or much improved. An open-label study has no placebo group, and the company's words "rapid onset" and "consistent" are its own description of the results.

The registration program is larger and still unread. Study '306, a 52-week, randomized, double-blind, placebo-controlled trial in 556 women, completed enrollment, with topline data expected in the first half of 2027. In men, Study '302 is a Phase 2/3 trial of 519 patients, and Study '304 is a confirmatory Phase 3 of 536. The company expects 12-month data from Study '302 and topline data from Study '304 in the second half of 2026. More than 1,000 men across the two studies received VDPHL01 or placebo.

The runway claim, then, depends on trials that have not yet reported. Chief executive Reid Waldman said the company looks forward to a "catalyst-rich remainder of 2026," which is a description of readouts still to come.

What the cash has to cover

Cash of $819.9 million sits against a net loss of $23.5 million in the second quarter alone and a $70.0 million net loss for 2025. The company's statement that the funds last into 2030 assumes its planned trials and a launch, both of which cost money before any revenue arrives. VDPHL01 is still an investigational drug, and the release speaks only of a potential launch.

Financing and what comes next

This update reports no new offering, and the release describes the May raise only in total, so it names no underwriter or placement agent. The next readouts are the 12-month data from Study '302 and the topline results from Study '304, both expected in the second half of 2026. Study '306 follows in the first half of 2027. The company says it is preparing for a possible commercial launch, and the runway it gives assumes that launch happens on the schedule it describes.

Report an error

Companies in this story

MANEVeradermics, IncorporatedNYSE · United StatesOpen the starter desk